Inhibiting COX-2/PGE2 pathway with biodegradable NIR-Ⅱ fluorescent polymeric nanoparticles for enhanced photodynamic immunotherapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer, Stress, Anesthesia, and Immune Response
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. Enhancement of photodynamic cancer therapy by physical and chemical factors10.1002/anie.201814098 ↗
2. Photo-reduction with NIR light of nucleus-targeting Pt(IV) nanoparticles for combined tumor-targeted chemotherapy and photodynamic immunotherapy10.1002/anie.202201486 ↗
3. Forging forward in photodynamic therapy10.1158/0008-5472.CAN-21-4122 ↗
4. Platinum-carbon-integrated nanozymes for enhanced tumor photodynamic and photothermal therapy
5. In vivo regenerable cerium oxide nanozyme-loaded pH/H2O2-responsive nanovesicle for tumor-targeted photothermal and photodynamic therapies10.1021/acsami.0c19074 ↗
6. Clinical development and potential of photothermal and photodynamic therapies for cancer10.1038/s41571-020-0410-2 ↗
7. Self-sacrificially degradable pseudo-semiconducting polymer nanoparticles that integrate NIR-II fluorescence bioimaging, photodynamic immunotherapy, and photo-activated chemotherapy10.1002/adma.202203820 ↗
8. NIR-light triggered dual-cascade targeting core-shell nanoparticles enhanced photodynamic therapy and immunotherapy10.1016/j.nantod.2021.101288 ↗
9. In vivo wireless photonic photodynamic therapy10.1073/pnas.1717552115 ↗
10. Conquering the hypoxia limitation for photodynamic therapy10.1002/adma.202103978 ↗
11. Photosensitizers for photodynamic therapy10.1002/adhm.201900132 ↗
12. Photosensitizer-based metal-organic frameworks for highly effective photodynamic therapy10.1016/j.msec.2021.112514 ↗
13. A self-degradable conjugated polymer for photodynamic therapy with reliable postoperative safety10.1002/advs.202104101 ↗
14. Dual-step irradiation strategy to sequentially destroy singlet oxygen-responsive polymeric micelles and boost photodynamic cancer therapy10.1016/j.biomaterials.2021.120959 ↗
15. Targeted and effective photodynamic therapy for cancer using functionalized nanomaterials10.1016/j.apsb.2016.01.007 ↗
16. Single-step synthesis of highly tunable multifunctional nanoliposomes for synergistic cancer therapy10.1021/acsami.2c00600 ↗
17. Molecular afterglow imaging with bright, biodegradable polymer nanoparticles10.1038/nbt.3987 ↗
18. AIEgens for biological process monitoring and disease theranostics10.1016/j.biomaterials.2017.09.004 ↗
19. Emerging photodynamic nanotherapeutics for inducing immunogenic cell death and potentiating cancer immunotherapy10.1016/j.biomaterials.2022.121433 ↗
20. Regulating glucose metabolism with prodrug nanoparticles for promoting photoimmunotherapy of pancreatic cancer10.1002/advs.202002746 ↗
21. Multispecific platinum(IV) complex deters breast cancer via interposing inflammation and immunosuppression as an inhibitor of COX-2 and PD-L110.1002/anie.202011273 ↗
22. Photodynamic therapy and anti-tumour immunity10.1038/nrc1894 ↗
23. Photodynamic therapy and immunity: an update10.1111/php.13253 ↗
24. Nanoparticle-based photothermal and photodynamic immunotherapy for tumor treatment10.1002/ijc.31717 ↗
25. Metformin liposome-mediated PD-L1 downregulation for amplifying the photodynamic immunotherapy efficacy10.1021/acsami.0c21743 ↗
26. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape10.1186/s12943-018-0928-4 ↗
27. Regulation and function of the PD-L1 checkpoint10.1016/j.immuni.2018.03.014 ↗
28. Tumor-targeted drug and CpG delivery system for phototherapy and docetaxel-enhanced immunotherapy with polarization toward M1-Type macrophages on triple negative breast cancers10.1002/adma.201904997 ↗
29. Detachable nanoparticle-enhanced chemoimmunotherapy based on precise killing of tumor seeds and normalizing the growing soil strategy10.1021/acs.nanolett.0c01415 ↗
30. COX-2 inhibitors decrease expression of PD-L1 in colon tumors and increase the influx of type I tumor-infiltrating lymphocytes10.1158/1940-6207.CAPR-21-0227 ↗
31. COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells10.1073/pnas.1612920114 ↗
32. COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models10.1126/scitranslmed.3008455 ↗
33. An assembled nanocomplex for improving both therapeutic efficiency and treatment depth in photodynamic therapy10.1002/anie.201802497 ↗
34. Carrier free photodynamic synergists for oxidative damage amplified tumor therapy
35. MTH1 inhibitor amplifies the lethality of reactive oxygen species to tumor in photodynamic therapy10.1126/sciadv.aaz0575 ↗
36. Histone γH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers10.1158/1078-0432.CCR-10-0523 ↗
37. Chemophototherapy: an emerging treatment option for solid tumors10.1002/advs.201600106 ↗
38. Redox-responsive dual drug delivery nanosystem suppresses cancer repopulation by abrogating doxorubicin-promoted cancer stemness, metastasis, and drug resistance
39. Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models10.1158/2159-8290.CD-18-0065 ↗
40. Immunogenic cell death and DAMPs in cancer therapy10.1038/nrc3380 ↗
41. H2O2 self‐producing single‐atom nanozyme hydrogels as light‐controlled oxidative stress amplifier for enhanced synergistic therapy by transforming “cold” tumors
42. Polypyrrole nanoenzymes as tumor microenvironment modulators to reprogram macrophage and potentiate immunotherapy10.1002/advs.202201703 ↗
43. Macrophage-based approaches for cancer immunotherapy10.1158/0008-5472.CAN-20-2990 ↗
44. Short overview on metabolomics approach to study pathophysiology of oxidative stress in cancer10.1016/j.redox.2017.08.009 ↗
45. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells10.1038/nature22359 ↗
46. Inhibition of glutamine utilization synergizes with immune checkpoint inhibitor to promote antitumor immunity10.1016/j.molcel.2020.10.015 ↗
47. Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance10.1038/s41551-021-00728-7 ↗
48. A systematic strategy of combinational blow for overcoming cascade drug resistance via NIR-light-triggered hyperthermia
49. Role of hypoxia in cancer therapy by regulating the tumor microenvironment10.1186/s12943-019-1089-9 ↗
50. Nanotechnology-enhanced immunotherapy for metastatic cancer